Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.

RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance

NASDAQ: RDHL.US [1]	
Last Trade:	10.47
Trade Time:	3:58 PM ET Mar 24, 2017
Change:	0.11 ↑ (1.062%)
Volume	41,611



TASE: RDHL [1]	
Last Trade:	377.00
Trade Time:	5:24 PM IT Mar 23, 2017
Change:	4.30 ↑ (1.154%)
Volume	98,899



Press Releases [View all]

Mar 22, 2017
RedHill Biopharma to Present at the 2017 MAP Conference

Mar 21, 2017
RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease

Mar 13, 2017
RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference

Events [View all]

Apr 7, 2017
BioCentury's Future Leaders in the Biotech Industry Conference

Apr 27, 2017
BEKINDA® R&D Day

Financials [View all]

Fourth Quarter Financial Results

Feb 23, 2017
Annual Report for Foreign Private Issuers (20-F)

RedHill Biopharma Ltd

Investor Relations Department
21 Haarbaa St
Tel Aviv 64739
Israel

Visit IR website
Sign-up for email alerts